DUBLIN–(BUSINESS WIRE)–The “Vasculitis Treatment: Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.
The global market for Vasculitis Treatment estimated at US$418.3 Million in the year 2020, is projected to reach a revised size of US$567.3 Million by 2027, growing at a CAGR of 4.4% over the analysis period 2020-2027.
Biologics, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$301.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 3.2% CAGR for the next 7-year period.
The U.S. Market is Estimated at $121.3 Million, While China is Forecast to Grow at 4% CAGR
The Vasculitis Treatment market in the U.S. is estimated at US$121.3 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$99.6 Million by the year 2027 trailing a CAGR of 4% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.
Immunosuppressants Segment to Record 3.9% CAGR
In the global Immunosuppressants segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$73.9 Million in the year 2020 will reach a projected size of US$97.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 23 Featured) –
- AB Science SA
- Ablynx NV
- Acorda Therapeutics, Inc.
- Antares Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Can-Fite BioPharma Ltd.
- Celgene Corporation
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences
- Daiichi Sankyo Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Hospira, Inc.
- Idera Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Lexicon Pharmaceuticals, Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Morphotek, Inc.
- Novartis AG
- Novo Nordisk A/S
- Regeneron Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi SA
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
- Vertex Pharmaceuticals Inc.
What’s New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies – Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Vasculitis Treatment – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/toe7jq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900